Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
27
PRPH Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
8.43%
Day range:
$0.67 - $0.75
52-week range:
$0.61 - $7.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.06x
P/B ratio:
0.46x
Volume:
352.9K
Avg. volume:
273.9K
1-year change:
-84.94%
Market cap:
$17.4M
Revenue:
$44.4M
EPS (TTM):
-$1.54
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, ProPhase Labs has 2437.72% upside to fair value with a price target of -- per share.
PRPH vs. S&P 500
-
Over the past 5 trading days, ProPhase Labs has overperformed the S&P 500 by 12.65% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ProPhase Labs does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProPhase Labs revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter ProPhase Labs reported revenues of $3.1M.
Earnings Growth
-
ProPhase Labs earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ProPhase Labs reported earnings per share of -$0.35.
Enterprise value:
34.1M
EV / Invested capital:
--
Price / LTM sales:
1.06x
EV / EBIT:
--
EV / Revenue:
2.67x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-2.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.1M
Return On Assets:
-30.23%
Net Income Margin (TTM):
-217.64%
Return On Equity:
-59.59%
Return On Invested Capital:
-47.22%
Operating Margin:
-252.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $146M | $62.7M | $12.8M | $8.4M | $3.1M | |
| Gross Profit | $84M | $30.6M | -$4.1M | $2.3M | -$165K | |
| Operating Income | $42.4M | -$15.4M | -$35.4M | -$6.5M | -$7.9M | |
| EBITDA | $44M | -$9.6M | -$27.3M | -$4.6M | -$5.4M | |
| Diluted EPS | $1.84 | -$0.63 | -$1.54 | -$0.30 | -$0.35 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.9M | $43.9M | $70.3M | $49.8M | $42.2M | |
| Total Assets | $23M | $72.6M | $97.9M | $91.7M | $91.8M | |
| Current Liabilities | $2.1M | $9.9M | $16.7M | $16.4M | $28.7M | |
| Total Liabilities | $12.3M | $24.4M | $30M | $35.3M | $53.7M | |
| Total Equity | $10.8M | $48.3M | $67.9M | $56.4M | $38.1M | |
| Total Debt | $10M | $10.1M | $8M | $7.3M | $17.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $23.1M | -$10.3M | -$14.2M | -$4.7M | -$4M | |
| Cash From Investing | $8.4M | -$5.1M | $1.2M | $332K | -$97K | |
| Cash From Financing | -$17.5M | -$6.7M | $13.4M | $1.2M | $2.9M | |
| Free Cash Flow | $20.8M | -$13.8M | -$16.6M | -$5.3M | -$4.2M | |
PRPH
Sector
Market Cap
$17.4M
$48.9M
Price % of 52-Week High
9.75%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
-13.28%
-0.74%
1-Year Price Total Return
-84.65%
-30.56%
Beta (5-Year)
-0.304
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.74
200-day SMA
Sell
Level
$3.19
Bollinger Bands (100)
Sell
Level
0.89 - 2.59
Chaikin Money Flow
Sell
Level
-14.3M
20-day SMA
Buy
Level
$0.69
Relative Strength Index (RSI14)
Sell
Level
43.10
ADX Line
Buy
Level
33.03
Williams %R
Neutral
Level
-63.471
50-day SMA
Sell
Level
$1.01
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
43.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1327)
Sell
CA Score
(Annual)
Level (-0.7583)
Sell
Beneish M-Score
(Annual)
Level (-1.4485)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.079)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Stock Forecast FAQ
In the current month, PRPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PRPH average analyst price target in the past 3 months is --.
-
Where Will ProPhase Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProPhase Labs share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About ProPhase Labs?
Analysts are divided on their view about ProPhase Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProPhase Labs is a Sell and believe this share price will drop from its current level to --.
-
What Is ProPhase Labs's Price Target?
The price target for ProPhase Labs over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProPhase Labs is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PRPH?
You can purchase shares of ProPhase Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProPhase Labs shares.
-
What Is The ProPhase Labs Share Price Today?
ProPhase Labs was last trading at $0.72 per share. This represents the most recent stock quote for ProPhase Labs. Yesterday, ProPhase Labs closed at $0.72 per share.
-
How To Buy ProPhase Labs Stock Online?
In order to purchase ProPhase Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is up 22.25% over the past day.
Sell
38
UNF alert for Jan 8
UniFirst [UNF] is up 20.59% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 19.13% over the past day.
